Genmab — November 2018
-
"While we have decided not to fund co-development of HuMax-TAC-ADC with ADC Therapeutics, we are pleased to still have 25% of the rights to the product, which has potential to become a first-in-class antibody-drug conjugate therapeutic in certain hematological cancer indications," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. https://ir.genmab.com/news-releases/news-release-details/genmab-retains-partial-rights-humax-tac-adc-will-not-exercise-co
-
Salesforce staves med stort S
-
Fra min nye bog: "Proinvestor.com er mest kendt for sit tårnhøje niveau indenfor pharma og biotek. Debattørerne er anonyme, men de mange kvalificerede spørgsmål og kommentarer viser tydeligt, at flere debatterer ud fra en medicinsk baggrund og/eller er beskæftigede inden for pharma og biotek. Der er i det hele taget mange ret nørdede fagdebatter her" .
-
Yderligere info: https://lilholmmedia.dk/
-
Har du også skrevet en sektion om os der ikke fatter det medicinske, men til gengæld stiller dumme spørgsmål
-
Jeg har skrevet, at der er plads til alle.
-
Og det er der bestemt
-
Har lige snakket med Hans-Henrik.. Han laver en analysevideo på Genmab i morgen.
-
https://ash.confex.com/ash/2018/webprogram/Paper115957.html Monster interessant, hvis CD20xCD3 kommer ud over rampen. CD37 abstractet ser også superinteressant ud. Den pipeline
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind